Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-FSHR CER-4-1BB/CD3zeta-expressing T lymphocytes

A preparation of autologous human T lymphocytes genetically modified to express a chimeric endocrine receptor (CER) targeting the human follicle stimulating hormone receptor (FSHR) and coupled to the signaling domains of 4-1BB (CD137) and CD3 zeta, with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous anti-FSHR CER-4-1BB/CD3zeta-expressing T lymphocytes target and bind to the FSHR on FSHR-expressing tumor cell surfaces, thereby killing FSHR-expressing tumor cells. FSHR is not normally expressed in healthy non-ovarian tissue, but is present on several types of ovarian, fallopian tube, or primary peritoneal cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-FSHR chimeric endocrine receptor-expressing T cells
autologous follicle stimulating hormone receptor-targeting chimeric endocrine receptor T cells
autologous FSHCER T cells
autologous FSHR-specific 4-1BB/CD3zeta CER T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search